Targeted therapies and immunotherapy in non-small-cell lung cancer.
Ontology highlight
ABSTRACT: Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumours completely changed the therapeutic landscape in lung cancers, harbouring specific gene mutations/translocations. Epidermal growth factors receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later led new insights in lung cancer biology knowledge. The use of specific tyrosine kinases inhibitors overturned the biological behaviour of EGFR mutation positive tumou
SUBMITTER: Cortinovis D
PROVIDER: S-EPMC4929979 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
ACCESS DATA